Critical Comparison: BeyondAirInc . (NASDAQ:XAIR) versus Intersect ENT (NASDAQ:XENT)
BeyondAirInc . (NASDAQ:XAIR) and Intersect ENT (NASDAQ:XENT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.
Volatility & Risk
BeyondAirInc . has a beta of -0.6, indicating that its stock price is 160% less volatile than the S&P 500. Comparatively, Intersect ENT has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.
12.8% of BeyondAirInc . shares are held by institutional investors. Comparatively, 96.5% of Intersect ENT shares are held by institutional investors. 18.1% of BeyondAirInc . shares are held by company insiders. Comparatively, 6.5% of Intersect ENT shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a breakdown of current recommendations and price targets for BeyondAirInc . and Intersect ENT, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BeyondAirInc . presently has a consensus target price of $9.00, indicating a potential upside of 8.17%. Intersect ENT has a consensus target price of $19.38, indicating a potential upside of 71.31%. Given Intersect ENT’s higher possible upside, analysts clearly believe Intersect ENT is more favorable than BeyondAirInc ..
This table compares BeyondAirInc . and Intersect ENT’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares BeyondAirInc . and Intersect ENT’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BeyondAirInc .||$7.72 million||17.73||-$6.56 million||($0.84)||-9.90|
|Intersect ENT||$109.14 million||3.37||-$42.99 million||($1.37)||-8.26|
BeyondAirInc . has higher earnings, but lower revenue than Intersect ENT. BeyondAirInc . is trading at a lower price-to-earnings ratio than Intersect ENT, indicating that it is currently the more affordable of the two stocks.
Intersect ENT beats BeyondAirInc . on 7 of the 13 factors compared between the two stocks.
BeyondAirInc . Company Profile
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.
Intersect ENT Company Profile
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.